AUTLAutolus Therapeutics plc

Nasdaq autolus.com


$ 6.38 $ 0.14 (2.24 %)    

Thursday, 28-Mar-2024 15:59:55 EDT
QQQ $ 443.93 $ -0.82 (-0.18 %)
DIA $ 397.72 $ 0.20 (0.05 %)
SPY $ 523.07 $ -0.10 (-0.02 %)
TLT $ 94.55 $ -0.08 (-0.08 %)
GLD $ 205.72 $ 2.62 (1.29 %)
$ 6.38
$ 6.25
$ 0.00 x 0
$ 6.38 x 300
$ 6.19 - $ 6.42
$ 1.61 - $ 7.45
695,027
na
1.7B
$ 1.78
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-21-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 needham-maintains-buy-on-autolus-therapeutics-maintains-9-price-target

Needham analyst Gil Blum maintains Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $9 price target.

 earnings-scheduled-for-march-14-2024

Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.

 needham-maintains-buy-on-autolus-therapeutics-raises-price-target-to-9

Needham analyst Gil Blum maintains Autolus Therapeutics (NASDAQ:AUTL) with a Buy and raises the price target from $8 to $9.

Core News & Articles

BioNTech SE (NASDAQ:BNTX, ", BioNTech", )))), a next-generation immunotherapy company pioneering novel therapies for ca...

 needham-maintains-buy-on-autolus-therapeutics-raises-price-target-to-8

Needham analyst Gil Blum maintains Autolus Therapeutics (NASDAQ:AUTL) with a Buy and raises the price target from $7 to $8.

 correction-fda-accepts-autolus-therapeutics-marketing-application-for-obecabtagene-autoleucel-for-relapsedrefractory-adult-b-cell-acute-lymphoblastic-leukemia-with-target-action-date-of-november-16-2024

Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cel...

 goldman-sachs-maintains-neutral-on-autolus-therapeutics-raises-price-target-to-48

Goldman Sachs maintains Autolus Therapeutics (NASDAQ:AUTL) with a Neutral and raises the price target from $3.2 to $4.8.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION